193 related articles for article (PubMed ID: 32404198)
21. Association KRAS G13D tumor mutated outcome in patients with chemotherapy refractory metastatic colorectal cancer treated with cetuximab.
Tural D; Selcukbiricik F; Erdamar S; Ozkurt CU; Yanmaz T; Mandel NM; Serdengeçti S
Hepatogastroenterology; 2013; 60(125):1035-40. PubMed ID: 23537520
[TBL] [Abstract][Full Text] [Related]
22. Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance.
Ali M; Kaltenbrun E; Anderson GR; Stephens SJ; Arena S; Bardelli A; Counter CM; Wood KC
Nat Commun; 2017 Jun; 8():15617. PubMed ID: 28593995
[TBL] [Abstract][Full Text] [Related]
23. Randomized phase II study of cetuximab versus irinotecan and cetuximab in patients with chemo-refractory KRAS codon G13D metastatic colorectal cancer (G13D-study).
Nakamura M; Aoyama T; Ishibashi K; Tsuji A; Takinishi Y; Shindo Y; Sakamoto J; Oba K; Mishima H
Cancer Chemother Pharmacol; 2017 Jan; 79(1):29-36. PubMed ID: 27878354
[TBL] [Abstract][Full Text] [Related]
24. Promising Therapeutic Efficacy of GC1118, an Anti-EGFR Antibody, against KRAS Mutation-Driven Colorectal Cancer Patient-Derived Xenografts.
Lee HW; Son E; Lee K; Lee Y; Kim Y; Lee JC; Lim Y; Hur M; Kim D; Nam DH
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31771279
[TBL] [Abstract][Full Text] [Related]
25. FoxO3a confers cetuximab resistance in RAS wild-type metastatic colorectal cancer through c-Myc.
Yu Y; Guo M; Wei Y; Yu S; Li H; Wang Y; Xu X; Cui Y; Tian J; Liang L; Peng K; Liu T
Oncotarget; 2016 Dec; 7(49):80888-80900. PubMed ID: 27825133
[TBL] [Abstract][Full Text] [Related]
26. KRAS p.G13D mutation and codon 12 mutations are not created equal in predicting clinical outcomes of cetuximab in metastatic colorectal cancer: a systematic review and meta-analysis.
Mao C; Huang YF; Yang ZY; Zheng DY; Chen JZ; Tang JL
Cancer; 2013 Feb; 119(4):714-21. PubMed ID: 22972628
[TBL] [Abstract][Full Text] [Related]
27. Upregulation of secreted phosphoprotein 1 affects malignant progression, prognosis, and resistance to cetuximab via the KRAS/MEK pathway in head and neck cancer.
Liu K; Hu H; Jiang H; Liu C; Zhang H; Gong S; Wei D; Yu Z
Mol Carcinog; 2020 Oct; 59(10):1147-1158. PubMed ID: 32805066
[TBL] [Abstract][Full Text] [Related]
28. 3-Bromopyruvate overcomes cetuximab resistance in human colorectal cancer cells by inducing autophagy-dependent ferroptosis.
Mu M; Zhang Q; Zhao C; Li X; Chen Z; Sun X; Yu J
Cancer Gene Ther; 2023 Oct; 30(10):1414-1425. PubMed ID: 37558749
[TBL] [Abstract][Full Text] [Related]
29. Negative correlation between acetyl-CoA acyltransferase 2 and cetuximab resistance in colorectal cancer.
Yuan Y; Sun X; Liu M; Li S; Dong Y; Hu K; Zhang J; Xu B; Ma S; Jiang H; Hou P; Lin Y; Gan L; Liu T
Acta Biochim Biophys Sin (Shanghai); 2023 Jun; 55(9):1467-1478. PubMed ID: 37310146
[TBL] [Abstract][Full Text] [Related]
30. Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients.
Hsu HC; Thiam TK; Lu YJ; Yeh CY; Tsai WS; You JF; Hung HY; Tsai CN; Hsu A; Chen HC; Chen SJ; Yang TS
Oncotarget; 2016 Apr; 7(16):22257-70. PubMed ID: 26989027
[TBL] [Abstract][Full Text] [Related]
31.
Xu JM; Wang Y; Wang YL; Wang Y; Liu T; Ni M; Li MS; Lin L; Ge FJ; Gong C; Gu JY; Jia R; Wang HF; Chen YL; Liu RR; Zhao CH; Tan ZL; Jin Y; Zhu YP; Ogino S; Qian ZR
Clin Cancer Res; 2017 Aug; 23(16):4602-4616. PubMed ID: 28424201
[No Abstract] [Full Text] [Related]
32. CircIFNGR2 enhances proliferation and migration of CRC and induces cetuximab resistance by indirectly targeting KRAS via sponging to MiR-30b.
Zhang Q; Zheng Y; Liu J; Tang X; Wang Y; Li X; Li H; Zhou X; Tang S; Tang Y; Wang X; He H; Li T
Cell Death Dis; 2023 Jan; 14(1):24. PubMed ID: 36639711
[TBL] [Abstract][Full Text] [Related]
33. The genomic landscape of response to EGFR blockade in colorectal cancer.
Bertotti A; Papp E; Jones S; Adleff V; Anagnostou V; Lupo B; Sausen M; Phallen J; Hruban CA; Tokheim C; Niknafs N; Nesselbush M; Lytle K; Sassi F; Cottino F; Migliardi G; Zanella ER; Ribero D; Russolillo N; Mellano A; Muratore A; Paraluppi G; Salizzoni M; Marsoni S; Kragh M; Lantto J; Cassingena A; Li QK; Karchin R; Scharpf R; Sartore-Bianchi A; Siena S; Diaz LA; Trusolino L; Velculescu VE
Nature; 2015 Oct; 526(7572):263-7. PubMed ID: 26416732
[TBL] [Abstract][Full Text] [Related]
34. Systems analysis identifies potential target genes to overcome cetuximab resistance in colorectal cancer cells.
Park SM; Hwang CY; Cho SH; Lee D; Gong JR; Lee S; Nam S; Cho KH
FEBS J; 2019 Apr; 286(7):1305-1318. PubMed ID: 30719834
[TBL] [Abstract][Full Text] [Related]
35. Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer.
Borrero-Palacios A; Cebrián A; Gómez Del Pulgar MT; García-Carbonero R; Garcia-Alfonso P; Aranda E; Elez E; López-López R; Cervantes A; Valladares M; Nadal C; Viéitez JM; Guillén-Ponce C; Rodríguez J; Hernández I; García JL; Vega-Bravo R; Puime-Otin A; Martínez-Useros J; Del Puerto-Nevado L; Rincón R; Rodríguez-Remírez M; Rojo F; García-Foncillas J
Sci Rep; 2019 Feb; 9(1):2589. PubMed ID: 30796344
[TBL] [Abstract][Full Text] [Related]
36. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
[TBL] [Abstract][Full Text] [Related]
37. ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer.
Johnson RM; Qu X; Lin CF; Huw LY; Venkatanarayan A; Sokol E; Ou FS; Ihuegbu N; Zill OA; Kabbarah O; Wang L; Bourgon R; de Sousa E Melo F; Bolen C; Daemen A; Venook AP; Innocenti F; Lenz HJ; Bais C
Nat Commun; 2022 Sep; 13(1):5478. PubMed ID: 36117191
[TBL] [Abstract][Full Text] [Related]
38. Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial.
Normanno N; Rachiglio AM; Lambiase M; Martinelli E; Fenizia F; Esposito C; Roma C; Troiani T; Rizzi D; Tatangelo F; Botti G; Maiello E; Colucci G; Ciardiello F;
Ann Oncol; 2015 Aug; 26(8):1710-4. PubMed ID: 25851630
[TBL] [Abstract][Full Text] [Related]
39. A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab.
Lee SK; Cho YH; Cha PH; Yoon JS; Ro EJ; Jeong WJ; Park J; Kim H; Il Kim T; Min DS; Han G; Choi KY
Exp Mol Med; 2018 Nov; 50(11):1-12. PubMed ID: 30459318
[TBL] [Abstract][Full Text] [Related]
40. Combination therapy with zoledronic acid and cetuximab effectively suppresses growth of colorectal cancer cells regardless of KRAS status.
Kato J; Futamura M; Kanematsu M; Gaowa S; Mori R; Tanahashi T; Matsuhashi N; Yoshida K
Int J Cancer; 2016 Mar; 138(6):1516-27. PubMed ID: 26437179
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
